Bandgap‐Engineered Pt x Te y :Ag 2 Te Composite Quantum Dots Enable Programmable NIR‐II Imaging and Photothermal‐Immune Synergistic Therapy
Source abstract
Abstract
ABSTRACT Real‐time monitoring of tumor spatiotemporal dynamics and precise modulation of the tumor immune microenvironment are pivotal for effective cancer treatment. However, current platforms lack the ability to integrate quantitative molecular imaging with spatially confined immune modulation. Here, we report a nanotheranostic platform Pt 2 Te 3 :Ag 2 Te‐αPD‐L1 (PAPD) based on bandgap‐engineered Pt x Te y :Ag 2 Te quantum dots. Platinum‐induced electronic reconfiguration enables programmable bandgap modulation, yielding tunable near‐infrared IIb emission spanning from 1550 to 2200 nm. Pt 2 Te 3 :Ag 2 Te quantum dots exhibit stable emission at 1730 nm and controllable mild photothermal effects. Conjugation with αPD‐L1 antibodies endows the PAPD platform with dual tumor‐targeting capability through EPR‐mediated passive accumulation and PD‐L1‐specific active recognition. Crucially, near‐infrared IIb molecular imaging enables quantitative monitoring of tumor targeting and therapeutic response, meanwhile mild photothermal modulation induces immune reprogramming that sensitizes tumors to immune checkpoint immunotherapy in vivo. This work establishes a generalizable quantum‐engineered nanotheranostic platform, offering a scalable strategy for precision cancer treatment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Gold and Silver Nanoparticles Synthesis and Applications · Biosensors and Analytical Detection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Zhejiang Cancer Hospital Hangzhou Institute of Medicine Chinese Academy of Sciences Hangzhou China
College of Chemistry and Molecular Sciences Wuhan University Wuhan China
College & Hospital of Stomatology Anhui Medical University Anhui Province Key Laboratory of Oral Diseases Research Hefei China
Funding
National Natural Science Foundation of China
References (50)
Show source-provided references
1. Advantages of Targeting the Tumor Immune Microenvironment Over Blocking Immune Checkpoint in Cancer Immunotherapy10.1038/s41392-020-00449-4 ↗
2. Innate Immune Cells in the Tumor Microenvironment10.1016/j.ccell.2021.05.016 ↗
3. Role of the Tumor Microenvironment in PD‐L1/PD‐1‐Mediated Tumor Immune Escape10.1186/s12943-018-0928-4 ↗
4. Molecular Determinants of Response to PD‐L1 Blockade Across Tumor Types10.1038/s41467-021-24112-w ↗
5. Combination Strategies With PD‐1/PD‐L1 Blockade: Current Advances and Future Directions10.1186/s12943-021-01489-2 ↗
6. Research Progress of Therapeutic Effects and Drug Resistance of Immunotherapy Based on PD‐1/PD‐L1 Blockade10.1016/j.drup.2022.100907 ↗
7. Mechanism and Role of Regulated Cell Death in Tumor Immunity and Immunotherapy10.1002/cac2.70064 ↗
8. Four‐Pronged Nanomotor Strategy Achieves Efficient TNBC Treatment via Synergistic Chemo‐Photothermal‐Immune Therapy10.1002/adfm.202504621 ↗
9. Tumoral/Exosomal PD‐L1 Silencing Reinforces Mild Photothermal Therapy by Relieving Systemic and Local Immunosuppression10.1016/j.cej.2024.149093 ↗
10. A Noble AuPtAg‐GOx Nanozyme for Synergistic Tumor Immunotherapy Induced by Starvation Therapy‐Augmented Mild Photothermal Therapy10.1002/advs.202202332 ↗
11. Directly Reprogrammed Natural Killer Cells for Cancer Immunotherapy10.1038/s41551-021-00768-z ↗
12. Single‐Atom Pd Nanozyme for Ferroptosis‐Boosted Mild‐Temperature Photothermal Therapy10.1002/anie.202101924 ↗
13. Metal‐Polyphenol Network Coated Bilirubin Nanoparticles for the Alleviation of Periodontitis via Mild Photothermal Therapy and Immunomodulatory Therapy10.1021/acsnano.5c05266 ↗
14. A Dual‐Layer MOF Microneedle Patch for Self‐Sensitized Mild Photothermal Therapy and Autophagy Regulation10.1002/adhm.202503743 ↗
15. Endogenous/Exogenous Dual‐Responsive Nanozyme for Photothermally Enhanced Ferroptosis‐Immune Reciprocal Synergistic Tumor Therapy10.1126/sciadv.adq3870 ↗
16. Bioactive Inorganic Nanomaterials for Cancer Theranostics10.1039/D2CS00352J ↗
17. Dual and Multi‐Immune Activation Strategies for Emerging Cancer Immunotherapy10.1016/j.mattod.2024.08.006 ↗
18. Burgeoning Strategies for Cancer Therapy Based on Ferroptosis Induced by Nanomaterials10.1002/adfm.202511199 ↗
19. Fluorescence‐Amplified Nanocrystals in the Second Near‐Infrared Window for In Vivo Real‐Time Dynamic Multiplexed Imaging10.1038/s41565-023-01422-2 ↗
20. In Vivo NIR‐II Fluorescence Imaging for Biology and Medicine10.1038/s41566-024-01391-5 ↗
21. Iron–Silver‐Modified Quantum Dots Act as Efficient Catalysts in Anti‐Cancer Multitherapy Through Controlled, Ultrasound‐Induced Oxidation10.1038/s41565-025-01943-y ↗
22. Dimeric PD‐L1 Specific Affibody Grafted Fe‐Based Nanosheets for Tumor‐Targeting Dual‐Mode Magnet Resonance Imaging and Enhancement of Photothermal‐Immunotherapy10.1016/j.cej.2025.159400 ↗
23. Engineered Magnetic Resonance Nanoprobes for Visualizing Tumor Programmed Cell Death Ligand 1 Level and Enhancing Synergistic Radio Immunotherapy10.1021/acsnano.5c04774 ↗
24. Molecular Gold Nanoclusters for Advanced NIR‐II Bioimaging and Therapy10.1021/acs.chemrev.4c00835 ↗
25. Nanocrystals for Deep‐Tissue In Vivo Luminescence Imaging in the Near‐Infrared Region10.1021/acs.chemrev.3c00506 ↗
26. Second Near‐Infrared Window Fluorescence Materials for In Vivo Dynamic Multiplexed Imaging10.1002/adfm.202422693 ↗
27. Nanomaterials in Tumor Immunotherapy: New Strategies and Challenges10.1186/s12943-023-01797-9 ↗
28. Breaking through the Size Control Dilemma of Silver Chalcogenide Quantum Dots via Trialkylphosphine‐Induced Ripening: Leading to Ag2 Te Emitting from 950 to 2100 nm10.1021/jacs.1c06661 ↗
29. Growth of Large Scale PtTe, PtTe2 and PtSe2 Films on a Wide Range of Substrates10.1007/s12274-020-2942-2 ↗
30. Enhanced Catalytic Ozonation for Eliminating CH3 SH via Graphene‐Supported Positively Charged Atomic Pt Undergoing Pt2+/Pt4+ Redox Cycle10.1021/acs.est.1c06938 ↗
31. Platinum Ion‐Doped TiO2: High Catalytic Activity of Pt2+ With Oxide Ion Vacancy in Ti4+ 1–xPt2+ xO2–x Compared to Pt4+ without Oxide Ion Vacancy in Ti4+ 1–xPt4+ x O210.1021/cm4015404 ↗
32. Controlling Stoichiometry in Ultrathin van der Waals Films: PtTe2, Pt2Te3, Pt3Te4, and Pt2Te210.1021/acsnano.2c04303 ↗
33. Anion‐Driven Bandgap Tuning of AgIn (S x Se1– x )2 Quantum Dots10.1021/acsnano.4c07774 ↗
34. Quad‐Band Short‐Wave Infrared Detection Using Bandgap‐Controlled Ag2Te Quantum Dots10.1002/adfm.202512679 ↗
35. Infrared Quantum Dots: Progress, Challenges, and Opportunities
36. Full‐Color Fluorescent Carbon Quantum Dots10.1126/sciadv.abb6772 ↗
37. Near‐Infrared II Fluorescence Imaging10.1038/s43586-024-00301-x ↗
38. Multiplexed Detection Using Quantum Dots as Photoluminescent Sensing Elements or Optical Labels10.1016/j.ccr.2021.214181 ↗
39. Safety Landscape of Therapeutic Nanozymes and Future Research Directions10.1002/advs.202407816 ↗
40. NIR‐II Fluorescent Thermophoretic Nanomotors for Superficial Tumor Photothermal Therapy10.1002/adma.202417440 ↗
41. Rhythmic Mild Photothermal Therapy Enhancing Anti‐PD‐L1 Response for Oral Squamous Cell Carcinoma Immunotherapy10.1016/j.cej.2024.150908 ↗
42. MRTF‐A‐NF‐κB/p65 Axis‐Mediated PDL1 Transcription and Expression Contributes to Immune Evasion of Non‐Small‐Cell Lung Cancer via TGF‐β10.1038/s12276-021-00670-3 ↗
43. Mechanisms and Consequences of Jak–STAT Signaling in the Immune System10.1038/ni.3691 ↗
44. Regulation of PD‐L1 Through Direct Binding of Cholesterol to CRAC Motifs10.1126/sciadv.abq4722 ↗
45. Crosstalk in NF‐κB Signaling Pathways10.1038/ni.2065 ↗
46. Antibody Drug Conjugates (ADCs)10.1097/01.HS9.0000936084.39805.f0 ↗
47. Quantum Dot‐Fab′ Conjugates as Compact Immunolabels for Microtubule Imaging and Cell Classification10.1021/acsnano.4c02215 ↗
48. Methods for Conjugating Antibodies With Quantum Dots10.3390/molecules30193999 ↗
49. Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of PD‐L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy10.1002/adma.202006003 ↗
50. Molecular Engineering of NIR‐II/IIb Emitting AIEgen for Multimodal Imaging‐Guided Photo‐Immunotherapy10.1002/smll.202300859 ↗